The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 years. Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive pain medicine.

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Sold as Journavx, the drug received U.S. approval in late January as a treatment for the short-lived “acute” pain typically felt after an operation or accident. Journavx works differently than ...

A UnitedHealth representative had no immediate comment. Vertex’s Journavx became the first new type of painkiller in more than two decades. The company has positioned the pill as a safer ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, “Journavx has been placed on Tier 3 of the Optum ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new pain medication Journavx in a less favorable Tier 3 coverage in two ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).